Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses

G. Dadaglio, C. Fayolle, X. Zhang, B. Ryffel, M. Oberkampf, T. Felix, S. Hervas-Stubbs, R. Osicka, P. Sebo, D. Ladant, C. Leclerc,

. 2014 ; 193 (4) : 1787-98.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15007991

Deciphering the mechanisms that allow the induction of strong immune responses is crucial to developing efficient vaccines against infectious diseases and cancer. Based on the discovery that the adenylate cyclase from Bordetella pertussis binds to the CD11b/CD18 integrin, we developed a highly efficient detoxified adenylate cyclase-based vector (CyaA) capable of delivering a large variety of Ags to the APC. This vector allows the induction of protective and therapeutic immunity against viral and tumoral challenges as well as against transplanted tumors in the absence of any added adjuvant. Two therapeutic vaccine candidates against human papilloma viruses and melanoma have been developed recently, based on the CyaA vector, and are currently in clinical trials. We took advantage of one of these highly purified vaccines, produced under good manufacturing practice-like conditions, to decipher the mechanisms by which CyaA induces immune responses. In this study, we demonstrate that CyaA binds both human and mouse CD11b(+) dendritic cells (DCs) and induces their maturation, as shown by the upregulation of costimulatory and MHC molecules and the production of proinflammatory cytokines. Importantly, we show that DCs sense CyaA through the TLR4/Toll/IL-1R domain-containing adapter-inducing IFN-β pathway, independent of the presence of LPS. These findings show that CyaA possesses the intrinsic ability to not only target DCs but also to activate them, leading to the induction of strong immune responses. Overall, this study demonstrates that Ag delivery to CD11b(+) DCs in association with TLR4/Toll/IL-1R domain-containing adapter-inducing IFN-β activation is an efficient strategy to promote strong specific CD8(+) T cell responses.

000      
00000naa a2200000 a 4500
001      
bmc15007991
003      
CZ-PrNML
005      
20150325131927.0
007      
ta
008      
150306s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.4049/jimmunol.1302974 $2 doi
035    __
$a (PubMed)25024388
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dadaglio, Gilles $u Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris F-75015, France; INSERM, U1041, Paris F-75015, France; gilles.dadaglio@pasteur.fr claude.leclerc@pasteur.fr.
245    10
$a Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses / $c G. Dadaglio, C. Fayolle, X. Zhang, B. Ryffel, M. Oberkampf, T. Felix, S. Hervas-Stubbs, R. Osicka, P. Sebo, D. Ladant, C. Leclerc,
520    9_
$a Deciphering the mechanisms that allow the induction of strong immune responses is crucial to developing efficient vaccines against infectious diseases and cancer. Based on the discovery that the adenylate cyclase from Bordetella pertussis binds to the CD11b/CD18 integrin, we developed a highly efficient detoxified adenylate cyclase-based vector (CyaA) capable of delivering a large variety of Ags to the APC. This vector allows the induction of protective and therapeutic immunity against viral and tumoral challenges as well as against transplanted tumors in the absence of any added adjuvant. Two therapeutic vaccine candidates against human papilloma viruses and melanoma have been developed recently, based on the CyaA vector, and are currently in clinical trials. We took advantage of one of these highly purified vaccines, produced under good manufacturing practice-like conditions, to decipher the mechanisms by which CyaA induces immune responses. In this study, we demonstrate that CyaA binds both human and mouse CD11b(+) dendritic cells (DCs) and induces their maturation, as shown by the upregulation of costimulatory and MHC molecules and the production of proinflammatory cytokines. Importantly, we show that DCs sense CyaA through the TLR4/Toll/IL-1R domain-containing adapter-inducing IFN-β pathway, independent of the presence of LPS. These findings show that CyaA possesses the intrinsic ability to not only target DCs but also to activate them, leading to the induction of strong immune responses. Overall, this study demonstrates that Ag delivery to CD11b(+) DCs in association with TLR4/Toll/IL-1R domain-containing adapter-inducing IFN-β activation is an efficient strategy to promote strong specific CD8(+) T cell responses.
650    _2
$a adaptorové proteiny vezikulární transportní $x imunologie $7 D033942
650    _2
$a adenylátcyklasový toxin $x imunologie $7 D037361
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny CD11b $x imunologie $7 D039481
650    _2
$a antigeny CD80 $x biosyntéza $7 D018122
650    _2
$a antigeny CD86 $x biosyntéza $7 D051940
650    _2
$a Bordetella pertussis $x imunologie $7 D001886
650    _2
$a buněčná diferenciace $x imunologie $7 D002454
650    _2
$a kultivované buňky $7 D002478
650    _2
$a dendritické buňky $x cytologie $x imunologie $7 D003713
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a interferon beta $x imunologie $7 D016899
650    _2
$a interleukin-1beta $x biosyntéza $7 D053583
650    _2
$a interleukin-6 $x biosyntéza $7 D015850
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši knockoutované $7 D018345
650    _2
$a receptor interferonu alfa-beta $x genetika $7 D053633
650    _2
$a receptory interleukinu-1 $x imunologie $7 D017472
650    _2
$a signální transdukce $x imunologie $7 D015398
650    _2
$a cytotoxické T-lymfocyty $x imunologie $7 D013602
650    _2
$a toll-like receptor 4 $x imunologie $7 D051197
650    _2
$a TNF-alfa $x biosyntéza $7 D014409
650    _2
$a tyrosin $x genetika $7 D014443
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fayolle, Catherine $u Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris F-75015, France; INSERM, U1041, Paris F-75015, France;
700    1_
$a Zhang, Xiaoming $u Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris F-75015, France; INSERM, U1041, Paris F-75015, France;
700    1_
$a Ryffel, Bernard $u Unité Mixte de Recherche 7355, Université d'Orléans-Centre National de la Recherche Scientifique, Laboratoire Immunologie et Neurogénétique Expérimentales et Moléculaires, Orléans 45071, France;
700    1_
$a Oberkampf, Marine $u Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris F-75015, France; INSERM, U1041, Paris F-75015, France;
700    1_
$a Felix, Tristan $u Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris F-75015, France; INSERM, U1041, Paris F-75015, France;
700    1_
$a Hervas-Stubbs, Sandra $u Division of Gene Therapy and Hepatology, Centre for Applied Medical Research, University of Navarra, Pamplona 31008, Spain;
700    1_
$a Osicka, Radim $u Institute of Microbiology of the Academy of Sciences of the Czech Republic, Verejna Vyzkumna Instituce, Videnska 1083, 142 20 Prague, Czech Republic;
700    1_
$a Sebo, Peter $u Institute of Microbiology of the Academy of Sciences of the Czech Republic, Verejna Vyzkumna Instituce, Videnska 1083, 142 20 Prague, Czech Republic;
700    1_
$a Ladant, Daniel $u Institut Pasteur, Unité de Biochimie des Interactions Macromoléculaires, Paris F-75015, France; and Centre National de la Recherche Scientifique, Unité Mixte de Recherche 3528, Paris F-75015, France.
700    1_
$a Leclerc, Claude $u Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris F-75015, France; INSERM, U1041, Paris F-75015, France; gilles.dadaglio@pasteur.fr claude.leclerc@pasteur.fr.
773    0_
$w MED00002741 $t Journal of immunology (Baltimore, Md. 1950) $x 1550-6606 $g Roč. 193, č. 4 (2014), s. 1787-98
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25024388 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150325132216 $b ABA008
999    __
$a ok $b bmc $g 1065264 $s 890791
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 193 $c 4 $d 1787-98 $i 1550-6606 $m The Journal of immunology $n J Immunol $x MED00002741
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...